2.39 0.11 (4.82%) | 02-12 18:59 | |||||||||||||
|
|
Short term | ![]() ![]() ![]() |
|||
Mid term | ![]() |
|||
Targets | 6-month : | 3.89 ![]() |
1-year : | 4.67 |
Resists | First : | 3.33 ![]() |
Second : | 4 |
Pivot price | 2.64 ![]() |
|||
Supports | First : | 2.25 ![]() |
Second : | 1.87 ![]() |
MAs | MA(5) : | 2.44 ![]() |
MA(20) : | 2.68 ![]() |
MA(100) : | 2.52 ![]() |
MA(250) : | 4.98 ![]() |
|
MACD | MACD : | -0.2 ![]() |
Signal : | -0.2 ![]() |
%K %D | K(14,3) : | 6.5 ![]() |
D(3) : | 5.2 ![]() |
RSI | RSI(14): 40.3 ![]() |
|||
52-week | High : | 12.73 | Low : | 1.61 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.[ MGX ] has closed above bottom band by 17.8%. Bollinger Bands are 27.2% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
If tomorrow: | Open lower | Open higher |
High: | 2.4 - 2.41 | 2.41 - 2.43 |
Low: | 2.21 - 2.23 | 2.23 - 2.25 |
Close: | 2.36 - 2.39 | 2.39 - 2.42 |
Metagenomi, Inc., a gene editing biotechnology company, develops therapeutics for patients using metagenomics-derived genome editing toolbox in the United States. The company's genome editing toolbox includes programmable nucleases, base editors, and RNA and DNA-mediated integration systems, such as prime editing systems and clustered regularly interspaced short palindromic repeat-associated transposases. It has a strategic collaboration and license agreement with ModernaTX, Inc. focusing on new genome editing system for in vivo human therapeutic applications; a development, option, and license agreement with Affini-T Therapeutics, Inc. to develop and commercialize gene edited T-cell receptor-based therapeutic products in the field of treatment, prevention, or diagnosis of human cancer; and a collaboration and license agreement with Ionis Pharmaceuticals, Inc. to research, develop, and commercialize investigational medicines using genome editing technologies. The company was incorporated in 2016 and is based in Emeryville, California.
Wed, 22 Jan 2025
People are buying the wrong stock thinking it's part of OpenAI's Stargate Project - Quartz
Wed, 11 Dec 2024
Metagenomi Presents Highly Specific and Efficient Genome Editing Tools at Nature Conference “RNA at the Bench and Bedside IV” - Yahoo Finance
Fri, 06 Dec 2024
Metagenomi CFO sells shares for $2,899 By Investing.com - Investing.com UK
Wed, 13 Nov 2024
Metagenomi Reports Business Updates and Third Quarter 2024 Financial Results - GlobeNewswire
Wed, 14 Aug 2024
Metagenomi Reports Business Updates and Second Quarter 2024 Financial Results - GlobeNewswire
Mon, 12 Aug 2024
Metagenomi, Inc. (MGX): This New Penny Stock Received a Positive Rating From Street Analysts - Yahoo Finance
Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
Exchange:
NASDAQ
|
|
Sector:
Healthcare
|
|
Industry:
Biotechnology
|
|
Shares Out | 37 (M) |
Shares Float | 23 (M) |
Held by Insiders | 28.8 (%) |
Held by Institutions | 36.2 (%) |
Shares Short | 2,170 (K) |
Shares Short P.Month | 1,480 (K) |
EPS | -2.25 |
EPS Est Next Qtrly | 0 |
EPS Est This Year | 0 |
EPS Est Next Year | 0 |
Book Value (p.s.) | 6.82 |
Profit Margin | -134.3 % |
Operating Margin | -194.4 % |
Return on Assets (ttm) | -14.9 % |
Return on Equity (ttm) | -30.4 % |
Qtrly Rev. Growth | -7 % |
Gross Profit (p.s.) | -1.06 |
Sales Per Share | 1.47 |
EBITDA (p.s.) | -2.23 |
Qtrly Earnings Growth | 0 % |
Operating Cash Flow | -103 (M) |
Levered Free Cash Flow | -74 (M) |
PE Ratio | -1.07 |
PEG Ratio | 0 |
Price to Book value | 0.34 |
Price to Sales | 1.62 |
Price to Cash Flow | -0.87 |
Dividend | 0 |
Forward Dividend | 0 |
Dividend Yield | 0% |
Dividend Pay Date | Invalid DateTime. |
Ex-Dividend Date | Invalid DateTime. |